Newsroom

featured

BioLamina appoints Brian Hawkins, PhD as new Chief Technology Officer (CTO).

Stockholm, March 3, 2025 BioLamina appoints Brian Hawkins, PhD, as new Chief Technology Officer (CTO). BioLamina AB, appoints Brian Hawkins […]

featured

Find our Biolaminin® 521 LN in the new PluriKit™ by PluriStyx

Find our Biolaminin® 521 LN in the new PluriKit™ by PluriStyx We are proud to have been chosen by PluriStyx […]

events

Webinar: Treating Blindness with Stem Cell Therapies

How close are we to one-shot stem cell therapies for eye disease? What are the critical factors for successful translation to the clinic? Join us for the panel discussion!

featured

BioLamina AB appoints Klaus Langhoff-Roos as new CEO.

Stockholm August 15, 2024 BioLamina appoints Klaus Langhoff-Roos as new CEO. BioLamina AB, a leading maker of reagents for stem […]

News & Events

BioLamina appoints Brian Hawkins, PhD as new Chief Technology Officer (CTO).

Find our Biolaminin® 521 LN in the new PluriKit™ by PluriStyx

Webinar: Treating Blindness with Stem Cell Therapies

BioLamina AB appoints Klaus Langhoff-Roos as new CEO.

BioLamina appoints Brian Hawkins, PhD as new Chief Technology Officer (CTO).

Find our Biolaminin® 521 LN in the new PluriKit™ by PluriStyx

Webinar: Treating Blindness with Stem Cell Therapies

Join us for our webinar with Prof. Dr. Kasri – neurodevelopmental disorder research with MEA and laminin

BioLamina AB appoints Klaus Langhoff-Roos as new CEO.

Meet us at ISSCR 2024, July 10–13

Meet us at ISCT 2024, May 29–June 1

Meet us at our next events!

Meet us at Mercia Stem Cell Alliance Meeting, December 4

Meet us at ISSCR Vienna, December 4–6

Meet us at ATMP Sweden, December 5–6

Meet us at ESGCT, October 24–27

Meet us at GSCN, September 13–15

Meet us at Tumour Microenvironment 3D Model Workshop

BioLamina AB announces appointment of new management team members

Meet us at our next events!